-Data support VCN-01 acceptable safety profile with encouraging biological and clinical activity, and-Data support VCN-01 acceptable safety profile with encouraging biological and clinical activity, andidentify recommended Phase 2 dose (RP2D)-
-Publication further supports the development of Synthetic Biologics’ novel oncolytic adenovirus (OV)platform-
Read more ...
Follows recent announcement of planned acquisition of VCN Biosciences by Synthetic Biologics.
Read more ...
VCN Biosciences Announces Publication in Peer-Reviewed Journal of Immunotherapy of Cancer on Clinical Data obtained with VCN-01 after intratumorally administration in patients with Pancreatic Cancer
Read more ...
Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors
Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid TumorsLead drug candidate VCN-01 demonstrated clinical activity in multiple Phase 1 clinical trialsDesigned for systemic delivery, high selectivity, and enhanced tumor accessVCN-01 granted Orphan Drug Designation in Pancreatic Cancer by the EMASynthetic Biologics and VCN Biosciences to host a conference call today, December 14th, at 10:00 a.m. Eastern Time
For Immediate Release
Read more ...
Barcelona, November 2nd, 2021.- VCN Biosciences, a clinical-stage immuno-oncology company focused on the development of the next generation of oncolytic adenoviruses, today announced the oral presentation at the upcoming 2021 International Oncolytic Virus Conference (IOVC) being held November 5-7, 2021, both virtually and in Sedona, Arizona.
Read more ...
Barcelona, February 24, 2021.- VCN Biosciences, a clinical-stage immuno-oncology company focused on the development of the next generation of oncolytic adenoviruses, today announced that VCN-01 at a dose of 3.3x1012 vp/patient can be safely administered in combination with Durbalumab when administered 15 days apart. Accordingly, in an Investigator Meeting, it was decided that VCN-01 will be further investigated at a higher dose of 1x1013 vp/patient in combination with Durvalumab.
Read more ...
Barcelona, March 24, 2021.- VCN Biosciences, a clinical-stage immuno-oncology company focused on the development of the next generation of oncolytic adenoviruses, today announced the publication of preclinical research on promising therapy VCN-11 in Peer-Reviewed Journal of Controlled Release.
Read more ...
Barcelona, November 27, 2020 – A team of researchers from SJD BarcelonaA team of researchers from SJD BarcelonaChildren’s Hospital and the biotechnology company VCN Biosciences, a Grifols company,has developed a world-first treatment which has prevented a child, who hadalready lost an eye to retinal cancer, from losing the other eye and becomingcompletely blind. As a result, Félix, who travelled from Venezuela to Barcelonaspecifically for the treatment, is now disease-free and retains his visual acuity, allowinghim to walk and play just as before. The treatment, which was administered as part ofa clinical trial, consists in injecting a genetically modified virus into the tumour-affectedeye. This virus can select, attack and destroy cancer cells.
Read more ...
September 3, 2019 –VCN Biosciences, a clinical–stage company with a pipeline of different oncolytic immuno-oncology products, will present clinical data obtainedwith its lead candidate VCN-01 in patients with pancreatic carcinoma at the upcoming annual meeting of the European Society of Medical Oncology (ESMO) in Barcelona, 27 September –1 October2019.
Read more ...
May 6, 2019 – VCN Biosciences, a clinical–stage company developing oncolytic immuno-oncology products today announced that Manel Cascallo, Chief Executive Officer, will present at the following upcoming investor conferences:
Read more ...